piperidines and 2-(4--(methylamino)phenyl)-6-hydroxybenzothiazole

piperidines has been researched along with 2-(4--(methylamino)phenyl)-6-hydroxybenzothiazole* in 3 studies

Trials

1 trial(s) available for piperidines and 2-(4--(methylamino)phenyl)-6-hydroxybenzothiazole

ArticleYear
Changes in brain amyloid-β accumulation after donepezil administration.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 45

    Recent studies using the mouse model of Alzheimer's disease (AD) have shown that donepezil administration reduces brain amyloid-β (Aβ) accumulation. This study investigated whether donepezil administration can reduce brain Aβ accumulation in human patients with AD. Ten patients with AD underwent two

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Brain; Donepezil; Female; Functional Neuroimaging; Humans; Indans; Male; Nootropic Agents; Piperidines; Positron-Emission Tomography; Thiazoles; Time Factors

2017

Other Studies

2 other study(ies) available for piperidines and 2-(4--(methylamino)phenyl)-6-hydroxybenzothiazole

ArticleYear
Cerebral serotonin 4 receptors and amyloid-β in early Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2011, Volume: 26, Issue:3

    The 5-HT4 receptor may play a role in memory and learning and 5-HT4 receptor activation has been suggested to modulate acetylcholine release and to reduce amyloid-β (Aβ) accumulation. The aim of this study was for the first time to investigate the in vivo cerebral 5-HT4 receptor binding in early Alzheimer disease (AD) patients in relation to cortical Aβ burden. Eleven newly diagnosed untreated AD patients (mean MMSE 24, range 19-27) and twelve age- and gender-matched healthy controls underwent a two-hour dynamic [11C]SB207145 PET scan to measure the binding potential of the 5-HT4 receptor. All AD patients and eight healthy controls additionally underwent a [11C]PIB PET scan to measure the cortical Aβ burden. When AD patients were defined on clinical criteria, no difference in cerebral 5-HT4 receptor binding between AD patients and healthy controls was found (p = 0.54). However, when individuals were reassigned to groups according to their amyloid status, the PIB-positive individuals had 13% higher 5-HT4 receptor levels than PIB-negative individuals (p = 0.02) and the importance of classification of groups is emphasized. The 5-HT4 receptor binding was a positively correlated to Aβ burden (p = 0.03) and negatively to MMSE score of the AD patients (p = 0.02). Our data suggests that cerebral 5-HT4 receptor upregulation starts at a preclinical stage of and continues while dementia is still at a mild stage, which contrasts other receptor subtypes. We speculate that this may either be a compensatory effect of decreased levels of interstitial 5-HT, an attempt to improve cognitive function, increase acetylcholine release or to counteract Aβ accumulation.

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles; Brain; Brain Chemistry; Cognition; Female; Humans; Image Processing, Computer-Assisted; Ligands; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Serotonin, 5-HT4; Thiazoles

2011
Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.
    Journal of Alzheimer's disease : JAD, 2010, Volume: 20, Issue:4

    Intrahippocampal injections of aggregated amyloid-beta (Abeta)1-42 in rats result in memory impairment and in reduction of hippocampal 5-HT2A receptor levels. In order to investigate how changes in 5-HT2A levels and functionality relate to the progressive accumulation of Abeta protein, we studied 5-HT2A receptor regulation in double transgenic AbetaPPswe/PS1dE9 mice which display excess production of Abeta and age-dependent increase in amyloid plaques. Three different age-groups, 4-month-old, 8- month-old, and 11-month-old were included in the study. [3H]-MDL100907, [3H]-escitalopram, and [11C]-PIB autoradiography was performed for measuring 5-HT2A receptor, serotonin transporter (SERT), and Abeta plaque levels in medial prefrontal cortex (mPFC), prefrontal cortex (PFC), frontoparietal cortex (FPC), dorsal and ventral hippocampus, and somatosensory cortex. To investigate 5-HT2A receptor functionality, animals were treated with the 5-HT2A receptor agonist DOI and head-twitch response (HTR) subsequently recorded. Expression level of the immediate early gene c-fos was measured by in situ hybridization. We found that the age-related increase in Abeta plaque burden was accompanied by a significant decrease in 5-HT2A receptor binding in mPFC in the 11-month-old group. The changes in 5-HT2A receptor binding correlated negatively with [11C]-PIB binding and were not accompanied by decreases in SERT binding. Correspondingly, 11-month-old transgenic mice showed diminished DOI-induced HTR and reduced increase in expression of c-fos mRNA in mPFC and FPC. These observations point towards a direct association between Abeta accumulation and changes in 5-HT2A receptor expression that is independent of upstream changes in the serotonergic system.

    Topics: Aging; Amphetamines; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Autoradiography; Citalopram; Data Interpretation, Statistical; Fluorobenzenes; Genes, fos; Head Movements; Humans; In Situ Hybridization; Indicators and Reagents; Male; Mice; Mice, Transgenic; Piperidines; Plaque, Amyloid; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles

2010